ELTP (Elite Pharmaceuticals) Current Accrued Expense: $0.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTP Elite Pharmaceuticals Inc ELTP
60 GF Score
Price $0.31
GF Value $0.51
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Elite Pharmaceuticals Current Accrued Expense?

Elite Pharmaceuticals ELTP -13.53% 60 Current Accrued Expense is $0.9 Mil as of Jun. 2026. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.51 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Elite Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.9 Mil.

Elite Pharmaceuticals's quarterly Current Accrued Expense increased from Dec. 2025 ($1.1 Mil) to Mar. 2026 ($1.4 Mil) but then declined from Mar. 2026 ($1.4 Mil) to Jun. 2026 ($0.9 Mil).

Elite Pharmaceuticals's annual Current Accrued Expense declined from Mar. 2024 ($0.9 Mil) to Mar. 2025 ($0.5 Mil) but then increased from Mar. 2025 ($0.5 Mil) to Mar. 2026 ($1.4 Mil).

Elite Pharmaceuticals Current Accrued Expense Related Terms

Elite Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Current Accrued Expense Chart

Elite Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.51 0.93 0.54 1.42

Elite Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 0.94 1.07 1.42 0.94
ELTP
60GF Score
Elite Pharmaceuticals Inc ELTP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.9 Mil mean?
Elite Pharmaceuticals (ELTP) has a Current Accrued Expense of $0.9 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Current Accrued Expense too high?
Elite Pharmaceuticals' current Current Accrued Expense is $0.9 Mil. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Current Accrued Expense compare to EOLS and EBS?
Elite Pharmaceuticals' Current Accrued Expense of $0.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Current Accrued Expense is $0.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.51, compared to a current price of $0.31 — trading 39.2% below its estimated fair value. The current Current Accrued Expense is $0.9 Mil. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Current Accrued Expense is $0.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.31 is trading 39.2% below its estimated GF Value™ of $0.51. GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ELTP:

  • Current Accrued Expense: $0.9 Mil
  • GF Value™: $0.51 vs. price of $0.31 (39.2% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score

Get the complete analysis for ELTP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$0.51
GF Value